These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1301 related articles for article (PubMed ID: 28975889)

  • 21. Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases.
    Majid S; Rydén L; Manjer J
    BMC Cancer; 2019 Jun; 19(1):626. PubMed ID: 31238899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center.
    Sargent RE; Siegel E; Ito F; Kramme K; Kraft E; Hendrix V; Carr AA; Nelson ME; Bian SX; Jayachandran P; Sener SF
    J Surg Oncol; 2023 Jul; 128(1):9-15. PubMed ID: 36933187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of a breast cancer nomogram for predicting nonsentinel node metastases after minimal sentinel node involvement: validation of the Helsinki breast nomogram.
    Ouldamer L; Arbion F; Balagny A; Fourquet F; Marret H; Body G
    Breast; 2013 Oct; 22(5):787-92. PubMed ID: 23473772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. When is a lymph node dissection a lymph node dissection? The number of lymph nodes resected in sentinel and axillary lymph node dissections.
    Olaya W; Wong J; Wong J; Morgan J; Kazanjian K; Lum S
    Ann Surg Oncol; 2013 Feb; 20(2):627-32. PubMed ID: 22956069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sentinel lymph node micrometastasis as a predictor of axillary tumor burden.
    Dabbs DJ; Fung M; Landsittel D; McManus K; Johnson R
    Breast J; 2004; 10(2):101-5. PubMed ID: 15009035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution.
    Grabau D; Dihge L; Fernö M; Ingvar C; Rydén L
    Eur J Surg Oncol; 2013 Jun; 39(6):601-7. PubMed ID: 23579175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
    Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
    Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A differential intra-operative molecular biological test for the detection of sentinel lymph node metastases in breast carcinoma. An extended experience from the first U.K. centre routinely offering the service in clinical practice.
    Babar M; Madani R; Thwaites L; Jackson PA; Devalia HL; Chakravorty A; Irvine TE; Layer GT; Kissin MW
    Eur J Surg Oncol; 2014 Mar; 40(3):282-8. PubMed ID: 24331309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sentinel node biopsy in breast cancer: five years experience from Denmark.
    Christiansen P; Friis E; Balslev E; Jensen D; Møller S;
    Acta Oncol; 2008; 47(4):561-8. PubMed ID: 18465323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.
    Fan YJ; Li JC; Zhu DM; Zhu HL; Zhao Y; Zhu XB; Wu G; Bai TT
    BMC Surg; 2023 Jul; 23(1):209. PubMed ID: 37495945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axillary lymph node dissection vs. sentinel node biopsy for early-stage clinically node-negative breast cancer: a systematic review and meta-analysis.
    Petousis S; Christidis P; Margioula-Siarkou C; Liberis A; Vavoulidis E; Margioula-Siarkou G; Vatopoulou A; Papanikolaou A; Mavromatidis G; Dinas K
    Arch Gynecol Obstet; 2022 Oct; 306(4):1221-1234. PubMed ID: 35249123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simple nomogram to evaluate the risk of nonsentinel node metastases in breast cancer patients with minimal sentinel node involvement.
    Meretoja TJ; Strien L; Heikkilä PS; Leidenius MH
    Ann Surg Oncol; 2012 Feb; 19(2):567-76. PubMed ID: 21792511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is repeat sentinel lymph node biopsy possible for surgical axillary staging among patients with ipsilateral breast tumor recurrence?
    Lu X; He M; Yu L; Gou Z
    Cancer; 2023 May; 129(10):1492-1501. PubMed ID: 36807239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN biopsy.
    Rydén L; Chebil G; Sjöström L; Pawlowski R; Jönsson PE
    Eur J Surg Oncol; 2007 Feb; 33(1):33-8. PubMed ID: 17174513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors of non-sentinel lymph node metastasis in breast cancer with 1-2 sentinel lymph node macrometastases underwent total mastectomy: a case-control study.
    Huang Z; Wu Z; Zou QQ; Xie YJ; Li LH; Huang YP; Wu FM; Huang D; Pan YH; Yang JR
    World J Surg Oncol; 2023 Apr; 21(1):125. PubMed ID: 37024930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One Step Nucleic Acid Amplification (OSNA) positive micrometastases and additional histopathological NSLN metastases: Results from a single institution over 53 months.
    Babar M; Madani R; Jackson P; Layer GT; Kissin MW; Irvine TE
    Surgeon; 2016 Apr; 14(2):76-81. PubMed ID: 25444440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy.
    Langer I; Marti WR; Guller U; Moch H; Harder F; Oertli D; Zuber M
    Ann Surg; 2005 Jan; 241(1):152-8. PubMed ID: 15622003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.